Actelion Ltd. considers a well-trained sales force so important that it will put its new sales team to work for no revenues in return for on-the-job training.

Last week Actelion struck a deal with Genentech Inc. to co-promote DNA's TNKase tenecteplase and develop and co-market Actelion's tezosentan. Part of the deal includes a loan from DNA to establish a 50-person sales team at Actelion, which initially